FDA approves Technivie (ombitasvir + paritaprevir + ritonavir) with ribavirin for Hepatitis C- AbbVie
The FDA has approved Technivie (ombitasvir, paritaprevir, and ritonavir tablets), from AbbVie, in combination with ribavirin (RBV) for the treatment of adults with genotype 4 (GT4) chronic hepatitis C virus (HCV) infection who do not have cirrhosis. Technivie is the first and only all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with GT4 chronic HCV infection.
Approval of Technivie is based on data from the PEARL-I study, which demonstrated 100 percent sustained virologic response rates at 12 weeks post-treatment (SVR12) in patients who received Technivie and RBV for 12 weeks. PEARL-I is an open-label Phase 2b study that evaluated the efficacy and safety of Technivie in GT4 chronic HCV patients without cirrhosis. The study included GT4 patients who were new to therapy (n=42/42) or who had failed previous treatment with pegylated interferon (pegIFN) and RBV (n=49/49). Additionally, 91 percent of patients who were new to therapy achieved SVR12 (n=40/44) after taking Technivie without RBV. In the treatment-naive group without RBV, on-treatment virologic breakthrough was reported in one patient (two percent), and two patients (five percent) experienced post-treatment relapse. There were no virologic failures in the other treatment arms. There were no discontinuations due to adverse events in these patients.
Comment: The combination of (ombitasvir + paritaprevir + ritonavir) with ribavirin was EU approved in January 2015 as Viekirax and approved in clearing the hepatitis C virus genotypes 1a, 1b and 4, including in patients with liver scarring.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma